Ignite Creation Date:
2024-05-06 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03535740
Status:
COMPLETED
Last Update Posted:
2023-08-25
First Post:
2018-05-09
Brief Title:
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive ALK Advanced Non-Small-Cell Lung Cancer NSCLC Progressed on Alectinib or Ceritinib
Sponsor:
Ariad Pharmaceuticals
Organization:
Takeda
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-01-31
Start Date Type:
ACTUAL
Primary Completion Date:
2020-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-28
Completion Date Type:
ESTIMATED
First Submit Date:
2018-05-09
First Submit QC Date:
May 22 2018
Study First Post Date:
2018-05-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-10-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-17
Last Update Post Date:
2023-08-25
Last Update Post Date Type:
ACTUAL